Persistence with statins and incident cataract: a population-based historical cohort study

Annals of Epidemiology
Gabriel ChodickVarda Shalev

Abstract

In recent years, there is a growing body of evidence suggesting that statins may have anti-inflammatory effects; consequently, it was hypothesized that statins may have a preventive effect against cataract. The study was carried out on a retrospective cohort of 180,291 new statin users in a large health organization in Israel. Study participants were followed between 1998 and 2007 for incident cataract or cataract extraction. During the study period 27,301 cataracts were diagnosed and 6,976 cataract extractions were performed among study participants. Persistence with statins was associated significantly (P < 0.001) with a reduced risk of cataract in men and women aged 45 to 74. Men aged 45-54 with a high (>80%) proportion of follow-up days covered with statins had an adjusted hazard ratio of 0.62 (95% confidence interval: 0.54-0.72), compared with patients with low persistence with statins. In elderly patients, no relationship or a positive relationship was observed. Persistent statin use was significantly protective for the incidence of cataract in men and women under 75 years of age.

References

Dec 31, 1991·Clinica Chimica Acta; International Journal of Clinical Chemistry·H G FieselerD Seidel
Jan 1, 1994·Ophthalmic Research·J SchmidtK von Bergmann
Jan 1, 1995·Survey of Ophthalmology·S K West, C T Valmadrid
May 26, 1998·JAMA : the Journal of the American Medical Association·J AvornJ LeLorier
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Oct 31, 2000·Epidemiology·A RuigómezJ Raniwala
Apr 13, 2001·JAMA : the Journal of the American Medical Association·G G SchwartzUNKNOWN Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators
Jul 12, 2001·Clinical & Experimental Ophthalmology·P N DimitrovC A McCarty
Sep 26, 2001·Archives of Internal Medicine·R G SchliengerC R Meier
Jun 7, 2002·Archives of Ophthalmology·Leon B Ellwein, Carol J Urato
Apr 19, 2003·QJM : Monthly Journal of the Association of Physicians·L SmeethA E Fletcher
Feb 5, 2004·European Journal of Epidemiology·Gabriel ChodickEhud Kookia
Apr 14, 2004·Archives of Ophthalmology·Nathan CongdonUNKNOWN Eye Diseases Prevalence Research Group
May 25, 2006·Mini Reviews in Medicinal Chemistry·Takanori WatanabeMunehoro Nakamura
Jun 22, 2006·JAMA : the Journal of the American Medical Association·Barbara E K KleinLisa M Grady
Oct 24, 2006·The British Journal of Ophthalmology·I BaharD Weinberger
Mar 28, 2007·American Journal of Ophthalmology·Jennifer S L TanJie Jin Wang

❮ Previous
Next ❯

Citations

Mar 17, 2011·European Journal of Clinical Pharmacology·Maarit Jaana KorhonenRisto Huupponen
Oct 7, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Galina LurieMarc T Goodman
Jun 19, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Chao-Lun LaiMei-Shu Lai
Mar 16, 2013·Expert Opinion on Drug Safety·Ishak Mansi, Eric Mortensen
Oct 11, 2011·American Journal of Ophthalmology·Donald S Fong, Kwun-Yee T Poon
Jul 31, 2013·Alimentary Pharmacology & Therapeutics·C Motzkus-FeagansK L Lapane
Oct 6, 2015·Ophthalmology·Shaza N Al-HolouUNKNOWN Age-Related Eye Disease Study 2 Research Group
Dec 6, 2014·The Canadian Journal of Cardiology·Stephanie J WiseG B John Mancini
Dec 7, 2013·Journal of Cardiovascular Pharmacology and Therapeutics·John B Kostis, Jeanne M Dobrzynski
Dec 5, 2014·Journal of Cardiovascular Pharmacology and Therapeutics·Diego Macías Saint-GeronsFerrán Catalá-López
Jul 12, 2018·Clinical Pharmacology and Therapeutics·Julien BezinAntoine Pariente
Jan 1, 2019·Cardiovascular Therapeutics·Carlos AlvesFrancisco Batel Marques
Jul 24, 2018·Current Vascular Pharmacology·S MohammadJ P Kitzmiller
Feb 20, 2015·International Orthopaedics·Min ZengYihe Hu
Nov 8, 2019·The Cochrane Database of Systematic Reviews·Alpo VuorioUma Ramaswami
Jul 17, 2012·Optometry and Vision Science : Official Publication of the American Academy of Optometry·Carolyn M MachanElizabeth L Irving
Jul 8, 2017·The Cochrane Database of Systematic Reviews·Alpo VuorioUma Ramaswami
Jul 1, 2017·Cell Biochemistry and Biophysics·Justyna WidomskaMarija Raguz
Jan 15, 2016·Ophthalmic Epidemiology·Jay C ErieDavid O Hodge
Aug 7, 2019·Medicina·Ioanna MylonaIoannis Tsinopoulos
Jun 5, 2021·Regulatory Toxicology and Pharmacology : RTP·Hsiao-Ling ChenChing-Tang Chang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.